BRUSSELS--(BUSINESS WIRE)--Regulatory News:
ASIT biotech (Paris:ASIT) (BSE:ASIT) (ASIT - BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, today announces that it has received a transparency notification dated 9 February, 2018, the result of which is - following a capital increase completed on 25 January 2019 - that SA SFPI now has 8.87% of the Company’s voting rights, and has thus decreased its stake below the 10% threshold.
The statement dated 9 February 2018 notably includes the following information:
- Purpose of the notification
Passive crossing of a threshold
- Notification by
A parent undertaking or a controlling person
- Person subject to the notification requirement
SFPI SA – Avenue Louise 32 b4, 1050 Brussels, Belgium
Etat Belge – Rue de la Loi 12, 1000 Brussels, Belgium
- Date of the transaction
25 January 2018
- Threshold crossed (%)
Downward crossing of the 10% threshold.
A total of 15,262,544 voting rights
- This notification is available on ASIT biotech’s website, in the Documentation / Regulated information section:
About ASIT biotech
ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of AIT product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech’s product pipeline entails two novel ASIT+™ product candidates targeting respiratory allergy with the highest prevalence (i.e. grass pollen: gp-ASIT+™ and house dust mite: hdm-ASIT+™), that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.
ASIT biotech has a headcount of 22 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.
Further information can be found at www.asitbiotech.com.